| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/12/2000 | EP1017667A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 07/12/2000 | EP1017664A1 C3a receptor ligands |
| 07/12/2000 | EP1017423A1 Cloning pigs using donor nuclei from differentiated cells |
| 07/12/2000 | EP1017422A1 Cloning using donor nuclei from non-serum starved, differentiated cells |
| 07/12/2000 | EP1017391A2 Sustained release tablet formulation to treat parkinson disease |
| 07/12/2000 | EP1017388A1 Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine |
| 07/12/2000 | EP1017386A1 GRANULAR PREPARATIONS OF 5-(2-ETHYL- 2$i(H)-TETRAZOL- 5-YL)-1-METHYL-1, 2,3,6-TETRAHYDROPYRIDINE |
| 07/12/2000 | EP1017381A1 Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome |
| 07/12/2000 | EP1017379A1 Therapeutic compositions |
| 07/12/2000 | EP1017375A2 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 07/12/2000 | EP1017372A1 Controlled release solid dosage forms of lithium carbonate |
| 07/12/2000 | EP1017279A1 Methods for regulating trka expression |
| 07/12/2000 | EP1017275A1 Polyamine treatment of neurological disorders |
| 07/12/2000 | EP0731802B1 N-substituted azabicycloalkane derivatives as neuroleptics etc. |
| 07/12/2000 | EP0720600B1 3-(3,4-dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases |
| 07/12/2000 | EP0719772B1 Optically active imidazolidinone derivative and process for producing the same |
| 07/12/2000 | EP0628041B1 Heterocyclic compounds and their preparation and use |
| 07/12/2000 | EP0555391B1 Certain imidazoquinoxalines; a new class of gaba brain receptor ligands |
| 07/12/2000 | CN1259962A Anti-vegf antibodies |
| 07/12/2000 | CN1259961A Humanized antibodies and method for forming same |
| 07/12/2000 | CN1259954A 3-substituted pyrido [3',4' : 4,5] thieno [2,3D} pyrimidine derivatives, prodn. and use thereof |
| 07/12/2000 | CN1259948A 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine compounds |
| 07/12/2000 | CN1259946A Ergoline derivatives and their use as somatostatin receptor antagonists |
| 07/12/2000 | CN1259869A Pharmaceutical compositions contg. cinchonine dichlorhydrate |
| 07/12/2000 | CN1259380A Medicine for giving up drug |
| 07/12/2000 | CN1259372A Medicine for treating sciatica |
| 07/11/2000 | US6087505 Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives |
| 07/11/2000 | US6087392 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 07/11/2000 | US6087378 The active benzo(b)thiophene compounds for treating osteoporosis and cardiovascular disorders, especially hyperlipidemia |
| 07/11/2000 | US6087372 Method of enhancing cognition with 2-(4-methoxyphenyl)-pyrazolo[4,3-c]quinolin-3-one |
| 07/11/2000 | US6087357 Piperazine derivatives as tachykinin antagonists |
| 07/11/2000 | US6087356 Anesthetizing the patient to produce a state of unconsciousness, administering dextromethorphan to reduce the feelings of withdrawal symptoms, administering an opioid antagonist to induce acute withdrawal |
| 07/11/2000 | US6087351 Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone |
| 07/11/2000 | US6087330 Process to inhibit binding of the integrin α4 β1 to VCAM-1 or fibronectin and cyclic peptides therefor |
| 07/11/2000 | US6087323 Use of neuregulins as modulators of cellular communication |
| 07/11/2000 | US6087186 Synthetic library of random oligomers, each member comprising an oligomer linked to a microchip encoded with information identifying structure of oligomer; for drug screening |
| 07/11/2000 | US6087168 Obtaining basal epidermal cells, transfecting with expression vectors coding for neurogenic transcription factors, adding antisense oligonucleotide to suppress negative regulators of neuronal differentiation, culturing with retinoid and factors |
| 07/11/2000 | US6087150 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| 07/11/2000 | CA2023340C (quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes |
| 07/11/2000 | CA2019231C Novel acetylcholinesterase inhibitors |
| 07/11/2000 | CA1341051C Crf antagonists |
| 07/11/2000 | CA1341050C Neurite growth regulatory factors |
| 07/06/2000 | WO2000039299A2 Streptococcus antigens |
| 07/06/2000 | WO2000039279A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | WO2000039249A1 Ume extract having medicinal effects and compositions containing the same |
| 07/06/2000 | WO2000039141A1 Inositol-containing hexasaccharides, their synthesis and their uses |
| 07/06/2000 | WO2000039136A2 Human brainiac-5 |
| 07/06/2000 | WO2000039128A1 5ht1 antagonists for antidepressant therapy |
| 07/06/2000 | WO2000039127A1 1h-imidazo[4,5-d]pyridazin-7-ones, 3h-imidazo[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (crf) receptor ligands |
| 07/06/2000 | WO2000039126A1 Method for preparing (r)- (+) -3 {1- [2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl]- 4-phenylpiperidin -4-yl}-1,1- dimethylurea, its salts solvates and/or hydrates |
| 07/06/2000 | WO2000039123A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 07/06/2000 | WO2000039122A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 07/06/2000 | WO2000039121A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 07/06/2000 | WO2000039120A2 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | WO2000039116A1 Aminopyrazole derivatives |
| 07/06/2000 | WO2000039114A2 Substituted oximes and hydrazones as neurokinin antagonists |
| 07/06/2000 | WO2000039110A1 Homopiperazine derivatives as selective emopamil inhibitors |
| 07/06/2000 | WO2000039105A1 1,4-diazacycloheptane derivatives useful in the treatment of neurological disorders |
| 07/06/2000 | WO2000039101A1 Pyrimidine compounds |
| 07/06/2000 | WO2000039100A1 Phthalazine derivatives, a process for the preparation thereof, and a pharmaceutical composition containing the same |
| 07/06/2000 | WO2000039096A1 2-methylimidazoline compounds |
| 07/06/2000 | WO2000039091A1 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| 07/06/2000 | WO2000039090A1 Process for the preparation of paroxetine acetate and analogues thereof |
| 07/06/2000 | WO2000039089A1 3-azabicyclo[3.1.0.] hexane derivatives as opiate receptors ligands |
| 07/06/2000 | WO2000039077A2 Thyroid receptor ligands |
| 07/06/2000 | WO2000039070A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | WO2000038785A2 Methods for treating certain diseases using naaladase inhibitors |
| 07/06/2000 | WO2000038720A1 Remedies for pain |
| 07/06/2000 | WO2000038701A1 Use of unsaponifiable matters of vegetable oils for preparing a medicine |
| 07/06/2000 | WO2000038686A1 Controlled release galantamine composition |
| 07/06/2000 | WO2000038684A1 (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain |
| 07/06/2000 | WO2000038677A1 Indole and indolizidine derivatives for the treatment of migraine |
| 07/06/2000 | WO2000038672A2 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 07/06/2000 | WO2000038656A1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient |
| 07/06/2000 | WO2000038655A1 Dosage forms comprising porous particles |
| 07/06/2000 | WO2000038653A1 Improved formulation for topical non-invasive application in vivo |
| 07/06/2000 | WO2000038649A1 Pharmaceutical composition for oral administration designed to prevent misuse at the expense of a third party |
| 07/06/2000 | WO2000038618A2 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 07/06/2000 | WO2000038578A1 Anti-nicotine and anti-alcohol article |
| 07/06/2000 | WO2000020024A3 Methods for the treatment of non-thyroid disorders |
| 07/06/2000 | WO2000020020A3 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 07/06/2000 | WO2000018352A3 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | WO2000014222A3 Gabab receptor subtypes gabab-r1c and gabab-r2 and heterodimers thereof |
| 07/06/2000 | WO1999064035A9 β2-ADRENERGIC RECEPTOR AGONISTS |
| 07/06/2000 | WO1999052514A3 Pharmaceutical composition and combination preparation for immunosuppressive therapy |
| 07/06/2000 | WO1999047535A9 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS |
| 07/06/2000 | CA2358687A1 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | CA2358315A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | CA2358067A1 (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain |
| 07/06/2000 | CA2356986A1 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | CA2356638A1 Indole and indolizidine derivatives for the treatment of migraine |
| 07/06/2000 | CA2356548A1 Human brainiac-5 |
| 07/06/2000 | CA2356319A1 Thyroid receptor ligands |
| 07/06/2000 | CA2356269A1 Pain control agent |
| 07/06/2000 | CA2356098A1 Use of unsaponifiable matters of vegetable oils for preparing a medicine |
| 07/06/2000 | CA2355891A1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient |
| 07/06/2000 | CA2355097A1 Inositol-containing hexasaccharides, their synthesis and their uses |
| 07/06/2000 | CA2354052A1 Methods for treating certain diseases using naaladase inhibitors |